GlassScriptPhysician profile
Yvonne M Curran
NPI 1518950039
$25,948.26
in general payments reported to CMS, 2019-2025
12 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,498 · 2020: $8,415 · 2021: $7,973 · 2022: $315 · 2023: $416 · 2024: $183 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17,146.12 | 2019-2023 | Austedo |
| Lilly USA, LLC | $7,291.87 | 2019-2024 | Emgality, Reyvow |
| Abbvie INC. | $532.71 | 2021-2023 | Ubrelvy, Qulipta |
| Pfizer INC. | $271.45 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $199.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $125.11 | 2019-2021 | |
| Boston Scientific Corporation | $113.96 | 2019 | |
| Stryker Corporation | $75.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.49 | 2022 | |
| Amgen INC. | $56.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.86 | 2021-2022 | |
| Allergan, INC. | $21.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvonne Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.